Argenx Appoints Sandrine Piret-Gerard as Chief Commercialization Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Argenx (ARGX) announced Sandrine Piret-Gerard has been appointed chief commercialization officer. Sandrine brings extensive commercial and medical affairs experience, most recently leading the U.S. commercial organization at Gilead (GILD) across virology and oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARGX
Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 1041 USD with a low forecast of 858.00 USD and a high forecast of 1264 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 847.720
Low
858.00
Averages
1041
High
1264
Current: 847.720
Low
858.00
Averages
1041
High
1264
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
Continue Reading
Argenx (ARGX) Receives FDA Priority Review for Vyvgart Expansion Application
- FDA Priority Review: Argenx announced that its supplemental Biologics License Application for Vyvgart, targeting AChR-Ab negative generalized myasthenia gravis, has received priority review from the FDA, marking a significant advancement in expanding treatment indications.
- Target Action Date: The FDA has set May 10, 2026, as the target action date for this application, and approval would further solidify Vyvgart's market position in the rare autoimmune disease treatment sector.
- Clinical Data Support: The application is supported by data from Argenx's Phase 3 ADAPT SERON study, which met the primary endpoint related to a gMG clinical measure over four weeks, demonstrating Vyvgart's potential in the new indication.
- Market Performance: Vyvgart generated $2.2 billion in global product net sales for Argenx in 2024, and approval for the new indication could significantly enhance future sales growth and market share.
Continue Reading